Topical Drug Best for Smallpox Vaccine Side Effects
87354
NEW YORK  - A variety of potentially  serious infections can occur after immunization with the  smallpox vaccine. Now, findings from an animal study suggest  that a topical form of cidofovir, an anti-viral drug, is better  than an intravenous form at treating such infections.
95322
NEW YORK  - There have been widespread  concerns that mercury-based preservatives used in vaccines  might impair the neurological development of children, but the  opposite seems to be true.
344081
A new and more potent version of the chickenpox vaccine has won federal approval to prevent shingles, the often excruciatingly painful disease that can strike the elderly when the chickenpox virus emerges after lying dormant for decades.
220475
A new vaccine that could put the pox on shingles for many adult sufferers of the often painful infection caused by the chickenpox virus has received federal approval, health officials said Friday.
293745
Giving young children the pneumococcal vaccine Prevnar has had a significant impact on pneumococcal diseases, such as pneumonia and middle ear infections, researchers report.
196941
BETHESDA, US: A new Sanofi-Aventis meningitis vaccine aimed at protecting adolescents throughout their college years is safe and effective but should undergo longer-term studies if approved, a panel of US experts concluded.
595690
NEW YORK  - Therapy with valacyclovir (Valtrex, GlaxoSmithKline), started within three months of infection with either herpes simplex virus type 1 (HSV-1) or HSV type 2 (HSV-2), reduces the rate of symptomatic outbreaks compared with placebo, Seattle investigators report in the Journal of Sexually Transmitted Diseases.
138223
Sep 10, 2004 (CIDRAP News) - A test of smallpox vaccine made by Aventis Pasteur in the 1950s show it is still effective even when diluted, suggesting that the United States has more than enough vaccine for everyone, according to a report this week in
218430
Therapy with valacyclovir  (Valtrex, GlaxoSmithKline), started within three months of  infection with either herpes simplex virus type 1 (HSV-1) or  HSV type 2 (HSV-2), reduces the rate of symptomatic outbreaks  compared with placebo, Seattle investigators report in the  Journal of Sexually Transmitted Diseases.
215115
Injecting flu vaccine into the skin instead of muscle could stretch limited supplies, two studies reported Wednesday. Researchers injected less than half the standard flu vaccine dose into the skin.
115276
An advisory committee to the World Health Organization has for the first time recommended that Russian and American scientists be allowed to manipulate a gene in the smallpox virus to speed
679060
Diluting smallpox vaccine that is more than 50 years old is almost 100 percent effective, which means the current US stockpile can be expanded if needed, a new study found.
446862
NEW YORK  - People with genital herpes are  often prescribed a drug, such as valacyclovir or acyclovir, to  take on an ongoing basis to reduce recurrences. However, while  both of these antivirals are very effective at suppressing  herpes virus shedding, neither completely blocks viral  replication, according to new research findings.
725134
NEW YORK  - Applying a topical anesthetic  half an hour beforehand reduces pain for children getting a  measles-mumps-rubella (MMR) shot, according to a report by  Canadian researchers.
279208
A chemical specially designed to thwart how the AIDS virus invades during sex offers scientists a new lead in the long quest for a vaginal gel that women could apply to protect themselves when men don't use a condom.    The experimental drug isn't ready for human testing yet, but it provided potent protection to female monkeys exposed to large amounts of an AIDS virus, researchers reported Thursday in the journal Science...
488059
NEW YORK  - Treatment with a nasal spray  containing the anti-fungal drug amphotericin B reduces the  swelling and inflammation that occurs with chronic  rhinosinusitis, a common cause of stuffy nose and facial pain,  new research shows.
14234
In a proof-of-concept study published this week in The Lancet, researchers report that GlaxoSmithKline&#39;s RTS,S/AS02A malaria vaccine candidate protected a significant percentage of children against uncomplicated malaria, infection, and even severe forms